Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
read more
Citations
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Erlotinib in previously treated non-small-cell lung cancer.
EGFR Antagonists in Cancer Treatment
Timeline: Chemotherapy and the war on cancer.
References
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Erlotinib in previously treated non-small-cell lung cancer.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Frequently Asked Questions (14)
Q2. What future works have the authors mentioned in the paper "Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase iii trial—intact 1" ?
Previous studies have shown that gefitinib is an active agent for a number of patients with advanced NSCLC, so further work is needed to identify subsets of patients who may benefit more from this therapy.
Q3. What were the common histology types?
The most common histology types were adenocarcinoma and squamous-cell carcinoma, seen in 504 (46.1%) and 328 patients (30.0%), respectively.
Q4. How long did the gefitinib group survive?
One-year survival rates were 43% and 41% for the 500 mg/d and 250 mg/d gefitinib groups, respectively, and 44% for the placebo group.
Q5. What was the overall significance level of the study?
The study was designed to have 90% power for a two-sided overall significance level test of the hypothesis that gefitinib increases survival relative to placebo given a hazard ratio of 1.33.
Q6. What is the overall incidence of ILD in the study?
Recently published data suggest that gefitinib might be associated with interstitial pneumonia [21]; however, in their study, the overall incidence of ILD was less than 1%, and no imbalance was identified across the three treatment arms in terms of pneumonitis/ILD-type events.
Q7. What were the predictors of worse survival?
In the posthoc multivariate analysis, a performance status of 2, weight loss, and bone and liver metastases were significant (P .05) predictors of worse survival outcome.
Q8. What was the significance level of the study?
All rights reserved.at an interim analysis, simulations with the adaptive procedure were used to calculate a nominal significance level of 4.4% for the final analysis.
Q9. What was the median survival time for the gefitinib groups?
Objective tumor response rates were 50.3% and 51.2% for the 500 mg/d and 250 mg/d gefitinib groups, respectively, and 47.2% in the placebo group (P not significant).
Q10. What was the role of the independent data monitoring committee?
An Independent Data Monitoring Committee provided ongoing guidance and recommendations for patient management, based on review of the formal interim efficacy analysis, and also reviewed safety data on an ad-hoc basis, as determined by a steering committee.
Q11. What was the proportion of patients withdrawn from treatment because of adverse events of any cause?
The proportion of patients withdrawn from treatment because of adverse events of any cause was higher (23.0%) for patients in the 500 mg/d group, compared with 14.5% and 11.3% for 250 mg/d and placebo groups, respectively.
Q12. What is the important information about the study?
Previous studies have shownthat gefitinib is an active agent for a number of patients with advanced NSCLC, so further work is needed to identify subsets of patients who may benefit more from this therapy.
Q13. What was the hazard ratio for gefitinib?
During the trial and for 30 days after the last dose of gefitinib or placebo, patients were monitored for adverse events, which were graded according to the National Cancer Institute Common Toxicity Criteria.
Q14. Who has been a consultant for the last 2 years?
Acted as a consultant within the last 2 years: Giuseppe Giaccone, AstraZeneca; Roy S. Herbst, AstraZeneca; Christian Manegold, AstraZeneca; Giorgio Scagliotti, AstraZeneca; Joan Schiller, AstraZeneca; Ronald Natale, AstraZeneca; Vincent Miller, AstraZeneca; Ulrich Gatzemeier, AstraZeneca; David H. Johnson, AstraZeneca.